These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Design of a robust infrastructure to monitor the safety of the pandemic A(H1N1) 2009 vaccination program in Taiwan. Huang WT; Chen WW; Yang HW; Chen WC; Chao YN; Huang YW; Chuang JH; Kuo HS Vaccine; 2010 Oct; 28(44):7161-6. PubMed ID: 20804804 [TBL] [Abstract][Full Text] [Related]
28. Strategy for surveillance of adverse drug events. Bright RA Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403 [No Abstract] [Full Text] [Related]
30. [Pharmacovigilance of new antidepressants: evaluation of neuro-psychobehavioral disorders]. Blayac JP; Hillaire-Buys D; Peyrière H Therapie; 1997; 52(2):117-22. PubMed ID: 9231505 [TBL] [Abstract][Full Text] [Related]
31. A conditional maximized sequential probability ratio test for pharmacovigilance. Li L; Kulldorff M Stat Med; 2010 Jan; 29(2):284-95. PubMed ID: 19941282 [TBL] [Abstract][Full Text] [Related]
32. FDA attempting to overcome major roadblocks in monitoring drug safety. Zielinski SL J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645 [No Abstract] [Full Text] [Related]
33. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use. Knopp MV; Balzer T; Esser M; Kashanian FK; Paul P; Niendorf HP Invest Radiol; 2006 Jun; 41(6):491-9. PubMed ID: 16763467 [TBL] [Abstract][Full Text] [Related]
34. [PSUR - Instrument for pharmacovigilance and patient safety. What pharmacists should know about periodic safety update reports]. Strehl E Med Monatsschr Pharm; 2009 Sep; 32(9):347-9. PubMed ID: 19795697 [No Abstract] [Full Text] [Related]
35. [Pharmacovigilance off the beaten track: herbal surveillance or pharmacovigilance of medicinal plants]. Castot A; Djezzar S; Deleau N; Guillot B; Efthymiou ML Therapie; 1997; 52(2):97-103. PubMed ID: 9231502 [TBL] [Abstract][Full Text] [Related]
36. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Wysowski DK; Swartz L Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284 [TBL] [Abstract][Full Text] [Related]
37. Short patent lives jeopardize drug and patient safety. Hondeghem LM; De Clerck F; Camm J J Cardiovasc Pharmacol; 2007 Oct; 50(4):353-7. PubMed ID: 18049301 [TBL] [Abstract][Full Text] [Related]
38. Adverse drug reaction monitoring in pediatric practice. Kshirsagar NA; Karande S Indian Pediatr; 1996 Dec; 33(12):993-8. PubMed ID: 9141798 [No Abstract] [Full Text] [Related]
39. [Pharmacovigilance as new direction of research]. Gaszner G; Makkos Z; Gaszner P Neuropsychopharmacol Hung; 2005 Dec; 7(4):194-8. PubMed ID: 16496484 [TBL] [Abstract][Full Text] [Related]
40. Dealing with variability: the role of pharmacovigilance. Waller PC J Pharm Pharmacol; 1994 May; 46 Suppl 1():445-9. PubMed ID: 8064564 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]